Kyverna Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Kyverna Therapeutics

27/03/2025 21:02

Kyverna Therapeutics Inc KYTX.OQ reported a quarterly adjusted loss of 88 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-26.86.  The mean expectation of five analysts for the quarter was for a loss of 84 cents per share. Wall Street expected results to range from -90 cents to -70 cents per share.

Reported revenue was zero​; analysts expected zero.

Kyverna Therapeutics Inc's reported EPS for the quarter was a loss of 88 cents​.

The company reported a quarterly loss of $37.49 million.

Kyverna Therapeutics Inc shares had fallen by 33.2% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 4.1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Kyverna Therapeutics Inc is $18.50

This summary was machine generated from LSEG data March 27 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.84
-0.88
Missed
Sep. 30 2024
-0.79
-0.80
Missed
Jun. 30 2024
-0.70
-0.67
Beat
Mar. 31 2024
-0.84
-1.12
Missed